JWH-018 and JWH-073: Δ 9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 1, 2012, Pages 37-45

  Ginsburg, Brett C ^a   Schulze, David R ^a   Hruba, Lenka ^a   McMahon, Lance R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; DRONABINOL; INDOLE DERIVATIVE; JWH 073; NAPHTHALEN 1 YL (1 BUTYLINDOL 3 YL)METHADONE; NAPHTHALEN 1 YL (1 PENTYLINDOL 3 YL)METHADONE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASSAY; BEHAVIOR; BINDING AFFINITY; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG BINDING; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINOGENS; INDOLES; MACACA MULATTA; MALE; MARIJUANA ABUSE; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 84055219353     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187757     Document Type: Article

References (33)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58.
2. 9- Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62.
3. Boisse NR and Okamoto M (1978) Physical dependence to barbital compared to pentobarbital. IV. Influence of elimination kinetics. J Pharmacol Exp Ther 204: 526-540. (Pubitemid 8329256)
4. Breivogel CS and Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336.
5. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, and Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917.
6. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
7. 9- tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35:1775-1787.
8. 9-tetrahydrocannabinol, CP 55, 940 and WIN 55, 212. J Pharmacol Exp Ther 271:1383-1390.
9. Gay M (2010) Synthetic marijuana spurs state bans. The New York Times; July 11, 2010; p A17.
10. Ginsburg BC, McMahon LR, Herrera CR, and Javors M (2012) Purity of synthetic cannabinoids sold online for recreational use. J Anal Toxicol, in press.
11. 9-Tetrahydrocannabinol produced discrimination in pigeons. Pharmacol Biochem Behav 3:771-774.
12. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, and Wood DM (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 34:252-260.
13. 2 receptor agonists. Bioorg Med Chem 13:89-112.
14. 9-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol 22:498-507.
15. 9-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl) 208:87-98.
16. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction, Lippincott- Raven, Philadelphia, PA.
17. Lile JA (2006) Pharmacological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. Exp Clin Psychopharmacol 14:20-33.
18. 9- tetrahydrocannabinol. Psychopharmacology (Berl) 203: 241-250.
19. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, and Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58-63.
20. 9- tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
21. 9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162:1060-1073.
22. 9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl) 198:487-495.
23. National Research Council (2003) Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research, National Academies Press, Washington, DC.
24. Simmons J, Cookman L, Kang C, and Skinner C (2011) Three cases of "spice"exposure. Clin Toxicol (Phila) 49:431-433.
25. Singh H, Schulze DR, and McMahon LR (2011) Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology 215:665-675.
26. 9- tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334:347-356.
27. Tallarida RJ (2000) Drug Synergism and Dose-Effect Data Analysis, Chapman and Hall/CRC, Boca Raton, FL.
28. Uchiyama N, Kikura-Hanajiri R, Ogata J, and Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31-38.
29. Wiley JL (1999) Cannabis: discrimination of "internal bliss"? Pharmacol Biochem Behav 64:257-260.
30. 9-tetrahydrocannabinol. Behav Pharmacol 4:581-585.
31. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, and Martin BR (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004. (Pubitemid 28277896)
32. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, and Kleinschmidt K (2011) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med http://dx.doi.org/10.1016/j. ajem.2011.05.013.
33. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, and Schulz K (2009) Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch Arztebl Int 106:464-467.